ArticleBMC nephrology2026
Effect of dotinurad versus febuxostat on the one-year eGFR slope in CKD patients with hyperuricemia: a retrospective cohort study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe renoprotective effects of urate-lowering therapy, especially with selective urate reabsorption inhibitors (SURIs), remain to be established in patients with chronic kidney disease (CKD). This study compared changes in the estimated glomerular filtration rate (eGFR) slope associated with the initiation of dotinurad (a SURI) versus febuxostat (a xanthine oxidase inhibitor) in patients with chronic kidney disease, mainly due to diabetic kidney disease or hypertensive nephrosclerosis.
methodsWe conducted a single-center retrospective cohort study of 81 adult CKD patients with hyperuricemia who were newly started on dotinurad (n = 31) or febuxostat (n = 50) between January 2020 and October 2023. The primary endpoint was the change in the annual eGFR slope in the 1-year period before and after therapy initiation, which was evaluated via a linear mixed-effects model adjusted for baseline differences and confounders.
resultsAccording to the multivariable-adjusted analyses, the change in the eGFR slope differed significantly between the two groups (interaction term for group × period × time, p = 0.048). In the dotinurad group, a declining eGFR trend of − 2.8 mL/min/1.73 m² per year (95% confidence interval [CI] − 6.0 to + 0.4) before treatment stabilized to + 1.4 mL/min/1.73 m² per year (95% CI − 1.0 to + 3.7) after one year of therapy. This within-group change (+ 4.2 mL/min/1.73 m² per year) was statistically significant (p = 0.021). No comparable change was observed in the febuxostat group, whose eGFR slope changed from − 0.3 (95% CI − 3.0 to + 2.5) to − 0.8 (95% CI − 2.6 to + 1.0) mL/min/1.73 m² per year (within-group change − 0.5, p = 0.731). This difference in slopes accounted for the overall difference in treatment effects between the two therapies. The proportion of patients who achieved the target serum uric acid concentration < 6.0 mg/dL at 12 months did not differ significantly between the groups, nor did the incidence of a ≥ 30% decline in the eGFR during follow-up.
conclusionsIn this CKD cohort, the initiation of dotinurad was associated with a more favorable change in the eGFR slope compared with febuxostat. However, considering the observational nature and the small sample size, these findings should be regarded as hypothesis-generating. Further large-scale studies are warranted to confirm these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.